Cancer Immunotherapy with Advanced Research
University of HertfordshireCancer Immunotherapy with Advanced Research MSc is a postgraduate degree at University of Hertfordshire, based in Hatfield, taught full-time over 1 year.
About this course
The use of the immune system in cancer therapy is a prevailing ambition in the field. You’ll gain expert knowledge of the numerous ways cancers and the immune system interact so you can learn how cancer immunotherapies are developed. We’ll provide a thorough understanding of immune effector mechanisms and cancer biology. You’ll develop a range of personal skills through self-directed learning and our problem-based approach to teaching.
Why choose this course?
- You’ll be taught by our expert staff and innovative speakers from the biopharmaceutical industry
- Our modern Science Building provides excellent facilities for laboratory experiments, including DNA and genomic analysis eg QPCR, protein and proteomic science (eg MALDI-ToF), cell culture and Enzyme-based assays, isolated tissue studies and immunohistochemistry
- When you graduate, you’ll be equipped to work in a broad range of fields including medical or pharmaceutical research and development, clinical trials, public health and epidemiology, academia research, medical writing and science journalism, education, or patent law
- We adopt a blended learning approach to teaching, focussing on problem-based scenarios so you can develop strong critical analysis skills. You’ll benefit from exposure to practical techniques and guaranteed laboratory-based research projects.
- If successful, you will have the opportunity to undertake an extended 12-month research project.
Study Options
This course is available in 2 study options:
Duration: 2 Years
Qualification: MSc
Location: Hatfield
Duration: 1 Year
Qualification: MSc
Location: Hatfield
Related Courses
Course Details
- Qualification
- MSc
- Study Mode
- Full-time
- Duration
- 1 Year
- Start Date
- 2025
- Academic Year
- 2025
- Campus / Location
- Hatfield
- Scheme
- Postgraduate
2025-entry data — 2026 offers may differ